NASDAQ:INSM - Insmed Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $25.49 +0.25 (+0.99 %) (As of 07/17/2018 11:24 AM ET)Previous Close$25.17Today's Range$25.17 - $25.6552-Week Range$11.49 - $33.94Volume11,751 shsAverage Volume674,457 shsMarket Capitalization$1.94 billionP/E Ratio-8.81Dividend YieldN/ABeta0.94 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey. Receive INSM News and Ratings via Email Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:INSM CUSIPN/A Webwww.insmed.com Phone908-977-9900 Debt Debt-to-Equity Ratio0.70 Current Ratio20.01 Quick Ratio20.01 Price-To-Earnings Trailing P/E Ratio-8.81 Forward P/E Ratio-6.14 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$4.71 per share Price / Book5.41 Profitability EPS (Most Recent Fiscal Year)($2.89) Net Income$-192,640,000.00 Net MarginsN/A Return on Equity-68.14% Return on Assets-46.47% Miscellaneous Employees214 Outstanding Shares76,620,000Market Cap$1,941.63 Insmed (NASDAQ:INSM) Frequently Asked Questions What is Insmed's stock symbol? Insmed trades on the NASDAQ under the ticker symbol "INSM." How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) posted its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.07. View Insmed's Earnings History. What price target have analysts set for INSM? 8 brokers have issued 1 year price objectives for Insmed's stock. Their predictions range from $31.00 to $54.00. On average, they anticipate Insmed's share price to reach $40.00 in the next year. This suggests a possible upside of 56.9% from the stock's current price. View Analyst Ratings for Insmed. What is the consensus analysts' recommendation for Insmed? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Insmed's key competitors? Some companies that are related to Insmed include Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM) and Ultragenyx Pharmaceutical (RARE). Who are Insmed's key executives? Insmed's management team includes the folowing people: Mr. William H. Lewis, Pres, CEO & Director (Age 49)Ms. Christine A. Pellizzari, Chief Legal Officer (Age 50)Mr. Roger Adsett, Chief Commercial Officer (Age 49)Dr. Paul Streck, Chief Medical Officer (Age 55)Mr. Paolo Tombesi, Chief Financial Officer (Age 54) Has Insmed been receiving favorable news coverage? News stories about INSM stock have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insmed earned a media sentiment score of 0.11 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 44.82 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. How do I buy shares of Insmed? Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Insmed's stock price today? One share of INSM stock can currently be purchased for approximately $25.49. How big of a company is Insmed? Insmed has a market capitalization of $1.94 billion. The biopharmaceutical company earns $-192,640,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Insmed employs 214 workers across the globe. How can I contact Insmed? Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected] MarketBeat Community Rating for Insmed (NASDAQ INSM)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 323 (Vote Outperform)Underperform Votes: 306 (Vote Underperform)Total Votes: 629MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?